Crinetics Pharmaceuticals, Inc.
General ticker "CRNX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.6B (TTM average)
Crinetics Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 37.0%.
Estimated limits based on current volatility of 2.4%: low 33.18$, high 34.78$
Factors to consider:
- Total employees count: 437 (+50.7%) as of 2024
- Top business risk factors: Financing risks, Geopolitical risks, Labor/talent shortage/retention, Operational and conduct risks, Pandemic risks
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [33.18$, 64.10$]
- 2026-12-31 to 2027-12-31 estimated range: [28.08$, 56.05$]
Financial Metrics affecting the CRNX estimates:
- Negative: with PPE of -9.7 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 3.88 > -0.60
- Positive: Shareholder equity ratio, % of 88.09 > 64.29
Short-term CRNX quotes
Long-term CRNX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $4.01MM | $1.04MM | $7.70MM |
| Operating Expenses | $226.62MM | $339.89MM | $524.47MM |
| Operating Income | $-222.61MM | $-338.85MM | $-516.77MM |
| Non-Operating Income | $13.28MM | $40.92MM | $51.63MM |
| R&D Expense | $168.53MM | $240.16MM | $332.06MM |
| Income(Loss) | $-209.33MM | $-297.94MM | $-465.14MM |
| Taxes | $0.00MM | $0.00MM | $0.18MM |
| Other Income(Loss) | $-5.20MM | $-0.47MM | $0.00MM |
| Net Income(Loss)* | $-214.53MM | $-298.41MM | $-465.32MM |
| Stockholders Equity | $539.11MM | $1,324.81MM | $992.08MM |
| Inventory | $0.00MM | $0.00MM | $2.02MM |
| Assets | $635.35MM | $1,434.59MM | $1,126.26MM |
| Operating Cash Flow | $-168.60MM | $-230.19MM | $-377.92MM |
| Capital expenditure | $4.69MM | $3.84MM | $5.76MM |
| Investing Cash Flow | $-200.41MM | $-574.82MM | $173.91MM |
| Financing Cash Flow | $391.24MM | $1,014.66MM | $40.61MM |
| Earnings Per Share** | $-3.69 | $-3.69 | $-4.95 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.